Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021201
Filing Date
2023-05-11
Accepted
2023-05-11 16:04:43
Documents
74
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20230331.htm   iXBRL 10-Q 1723604
2 EX-31.1 glue-ex31_1.htm EX-31.1 20647
3 EX-31.2 glue-ex31_2.htm EX-31.2 20631
4 EX-32.1 glue-ex32_1.htm EX-32.1 19871
  Complete submission text file 0000950170-23-021201.txt   7142963

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT glue-20230331_cal.xml EX-101.CAL 40659
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT glue-20230331_def.xml EX-101.DEF 192109
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT glue-20230331_pre.xml EX-101.PRE 364190
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT glue-20230331.xsd EX-101.SCH 53867
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT glue-20230331_lab.xml EX-101.LAB 453291
68 EXTRACTED XBRL INSTANCE DOCUMENT glue-20230331_htm.xml XML 1223407
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 23910871
SIC: 2836 Biological Products, (No Diagnostic Substances)